Literature DB >> 22674166

Measurements of β-arrestin recruitment to activated seven transmembrane receptors using enzyme complementation.

Daniel L Bassoni1, William J Raab, Philip L Achacoso, Chin Yee Loh, Tom S Wehrman.   

Abstract

The recruitment of arrestins to activated 7TMRs results in the activation of alternative signaling pathways, quenching of G-protein activation, and coupling to clathrin-mediated endocytosis. The nearly ubiquitous involvement of arrestin in 7TMR signaling has spurred the development of several methods for monitoring this interaction in mammalian cells. Nonetheless, few maintain the reproducibility and precision necessary for drug discovery applications. Enzyme fragment complementation technology (EFC) is an emerging protein-protein interaction technology based on the forced complementation of a split enzyme that has proven to be highly effective in monitoring the formation of GPCR-arrestin complexes. In these systems, the target proteins are fused to two fragments of an enzyme that show little or no spontaneous complementation. Interaction of the two proteins forces the complementation of the enzyme, resulting in an enzymatic measure of the protein interaction. This chapter discusses the utility and methods involved in using the PathHunter β-galactosidase complementation system to monitor arrestin recruitment and the advantages of exploiting this pathway in the characterization of 7TMR function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22674166     DOI: 10.1007/978-1-61779-909-9_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  18 in total

1.  Discovery of Diphenylacetamides as CXCR7 Inhibitors with Novel β-Arrestin Antagonist Activity.

Authors:  Elnaz Menhaji-Klotz; Jessica Ward; Janice A Brown; Paula M Loria; Carina Tan; Kevin D Hesp; Keith A Riccardi; John Litchfield; Markus Boehm
Journal:  ACS Med Chem Lett       Date:  2020-05-14       Impact factor: 4.345

2.  Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor.

Authors:  Neil T Burford; Mary J Clark; Tom S Wehrman; Samuel W Gerritz; Martyn Banks; Jonathan O'Connell; John R Traynor; Andrew Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-10       Impact factor: 11.205

3.  Biased agonism as a mechanism for differential signaling by chemokine receptors.

Authors:  Sudarshan Rajagopal; Daniel L Bassoni; James J Campbell; Norma P Gerard; Craig Gerard; Tom S Wehrman
Journal:  J Biol Chem       Date:  2013-10-21       Impact factor: 5.157

4.  Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.

Authors:  Neil T Burford; Kathryn E Livingston; Meritxell Canals; Molly R Ryan; Lauren M L Budenholzer; Ying Han; Yi Shang; John J Herbst; Jonathan O'Connell; Martyn Banks; Litao Zhang; Marta Filizola; Daniel L Bassoni; Tom S Wehrman; Arthur Christopoulos; John R Traynor; Samuel W Gerritz; Andrew Alt
Journal:  J Med Chem       Date:  2015-05-07       Impact factor: 7.446

5.  Distinct conformations of GPCR-β-arrestin complexes mediate desensitization, signaling, and endocytosis.

Authors:  Thomas J Cahill; Alex R B Thomsen; Jeffrey T Tarrasch; Bianca Plouffe; Anthony H Nguyen; Fan Yang; Li-Yin Huang; Alem W Kahsai; Daniel L Bassoni; Bryant J Gavino; Jane E Lamerdin; Sarah Triest; Arun K Shukla; Benjamin Berger; John Little; Albert Antar; Adi Blanc; Chang-Xiu Qu; Xin Chen; Kouki Kawakami; Asuka Inoue; Junken Aoki; Jan Steyaert; Jin-Peng Sun; Michel Bouvier; Georgios Skiniotis; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

6.  A Pharmacochaperone-Based High-Throughput Screening Assay for the Discovery of Chemical Probes of Orphan Receptors.

Authors:  Camilo J Morfa; Daniel Bassoni; Andras Szabo; Danielle McAnally; Haleli Sharir; Becky L Hood; Stefan Vasile; Tom Wehrman; Jane Lamerdin; Layton H Smith
Journal:  Assay Drug Dev Technol       Date:  2018-09-22       Impact factor: 1.738

Review 7.  Efficacy and ligand bias at the μ-opioid receptor.

Authors:  E Kelly
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

8.  Allosteric "beta-blocker" isolated from a DNA-encoded small molecule library.

Authors:  Seungkirl Ahn; Alem W Kahsai; Biswaranjan Pani; Qin-Ting Wang; Shuai Zhao; Alissa L Wall; Ryan T Strachan; Dean P Staus; Laura M Wingler; Lillian D Sun; Justine Sinnaeve; Minjung Choi; Ted Cho; Thomas T Xu; Gwenn M Hansen; Michael B Burnett; Jane E Lamerdin; Daniel L Bassoni; Bryant J Gavino; Gitte Husemoen; Eva K Olsen; Thomas Franch; Stefano Costanzi; Xin Chen; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-27       Impact factor: 11.205

9.  Monoclonal anti-β1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment.

Authors:  Catherine J Hutchings; Gabriella Cseke; Greg Osborne; Jeanette Woolard; Andrei Zhukov; Markus Koglin; Ali Jazayeri; Jahnavi Pandya-Pathak; Christopher J Langmead; Stephen J Hill; Malcolm Weir; Fiona H Marshall
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

Review 10.  Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications.

Authors:  N T Burford; J R Traynor; A Alt
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.